[1]马晓云,李全福,金高娃.放疗联合恩度在不同EGFR基因突变非小细胞肺癌脑转移患者中的应用[J].中国医学物理学杂志,2026,43(2):240-244.[doi:DOI:10.3969/j.issn.1005-202X.2026.02.014]
　MA Xiaoyun,LI Quanfu,JIN Gaowa.Role of radiotherapy combined with Endostar in non-small cell lung cancer patients with brain metastasis and different EGFR mutations[J].Chinese Journal of Medical Physics,2026,43(2):240-244.[doi:DOI:10.3969/j.issn.1005-202X.2026.02.014]
点击复制

放疗联合恩度在不同EGFR基因突变非小细胞肺癌脑转移患者中的应用()

《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]

卷:
43卷
期数:
2026年第2期
页码:
240-244
栏目:
医学生物物理
出版日期:
2026-02-27

文章信息/Info

Title:
Role of radiotherapy combined with Endostar in non-small cell lung cancer patients with brain metastasis and different EGFR mutations
文章编号:
1005-202X（2026）02-0240-05
作者:
马晓云1; 李全福2; 金高娃2
1.内蒙古医科大学赤峰临床医学院， 内蒙古 赤峰 024000； 2.内蒙古医科大学鄂尔多斯临床医学院， 内蒙古 鄂尔多斯 017000
Author(s):
MA Xiaoyun1;  LI Quanfu2;  JIN Gaowa2
1. Chifeng Clinical Medical College, Inner Mongolia Medical University, Chifeng 024000, China 2. Ordos Clinical Medical College, Inner Mongolia Medical University, Ordos 017000, China
关键词:
非小细胞肺癌; 脑转移瘤; 放射治疗; 恩度; 表皮生长因子受体; 基因突变
Keywords:
Keywords: non-small cell lung cancer brain metastasis radiotherapy Endostar epidermal growth factor receptor gene mutation
分类号:
R816.1；R734.2
DOI:
DOI:10.3969/j.issn.1005-202X.2026.02.014
文献标志码:
A
摘要:
目的：分析放疗联合恩度在不同表皮生长因子受体（EGFR）基因突变非小细胞肺癌（NSCLC）脑转移患者中的应用。方法：收集经病理及影像学诊断的NSCLC脑转移患者资料，所有患者全脑放疗（WBRT）或者WBRT联合立体定向放射外科，经基因检测有EGFR突变的患者同时给予口服TKI治疗，根据患者脑转移临床表现的严重程度及病人和家属意愿给予同步联合内皮抑素（恩度）治疗。所有患者比较治疗前后脑水肿体积变化，并随访总生存期（OS）。结果：（1）治疗后全部病人平均脑水肿体积均较放疗前减小。在联合恩度治疗的患者中，联合突变组放疗后脑水肿体积缩小较联合野生组显著，且联合突变组脑水肿体积变化有统计学意义（P<0.05）。在未联合恩度治疗的患者中，未联合突变组放疗后脑水肿体积缩小较未联合野生组显著，未联合突变组脑水肿体积变化有统计学意义（P<0.05）。（2）联合恩度组和未联合恩度组患者的中位OS分别为31.4月和15.9月（P=0.029）。EGFR突变组和野生组的中位OS分别为24.2月和18.4月（P=0.733）。在EGFR突变型患者中，联合恩度与未联合恩度的中位OS分别是24.2月和15.3月（P=0.09）。（3）在治疗后1月随访时，联合恩度组（n=11）有6例CR+PR，4例SD，1例PD；未联合恩度组（n=14）有6例CR+PR，8例SD，0例PD。结论：放疗联合恩度可以提高NSCLC脑转移患者生存期。
Abstract:
Abstract: Objective To investigate the application of radiotherapy combined with Endostar in patients with brain metastases from non-small cell lung cancer (NSCLC) harboring different epidermal growth factor receptor (EGFR) mutations. Methods Clinical data of patients with pathologically and radiologically confirmed brain metastases from NSCLC were collected. All patients received whole brain radiotherapy alone or in combination with stereotactic radiosurgery. Those with EGFR mutations detected through genetic testing were additionally administered oral TKI therapy. Concurrent endostatin (Endostar) treatment was given based on the severity of clinical manifestations related to brain metastases as well as the willingness of patients and their families. Changes in brain edema volume before and after treatment were compared, and overall survival (OS) was followed up. Results (1) The average brain edema volume was significantly reduced after radiotherapy in all patients. Among patients receiving Endostar combination treatment, the decrease in brain edema volume in the EGFR-mutant group after radiotherapy was significantly greater than that in the wild-type group, and the brain edema volume changes in EGFR-mutant group was statistically significant (P<0.05). In patients receiving treatment without Endostar, the decrease in brain edema volume after radiotherapy was more pronounced in the EGFR-mutant group than in the wild-type group, and a significant brain edema volume change was observed in the EGFR-mutant group (P<0.05). (2) The median OS of the patients receiving Endostar combination treatment versus those receiving treatment without Endostar was 31.4 months versus 15.9 months (P=0.029). The median OS of the EGFR-mutant group versus the wild-type group were 24.2 months versus 18.4 months (P=0.733). In EGFR-mutant patients, the median OS of those receiving Endostar combination treatment versus those receiving treatment without Endostar was 24.2 months versus 15.3 months, (P=0.09). (3) At the 1 month follow-up after treatment, among 11 patients receiving Endostar combination treatment, 6 cases achieved CR+PR, 4 cases showed SD, and 1 case had PD while in 14 patients receiving treatment without Endostar, there were 6 cases of CR+PR, 8 cases of SD, and 0 cases of PD. Conclusion The combination of radiotherapy and Endostar can improve the survival outcome of NSCLC patients with brain metastases.

相似文献/References:

[1]刘旭红,陈 晓,赵 彪,等.非小细胞肺癌三维适形计划和调强计划剂量学比较与分析[J].中国医学物理学杂志,2014,31(02):4740.[doi:10.3969/j.issn.1005-202X.2014.02.005]
[2]黄宝添,吴丽丽,陈创珍,等.AXB与AAA算法在Ⅰ期非小细胞肺癌立体定向治疗中的剂量学比较[J].中国医学物理学杂志,2014,31(03):4881.[doi:10.3969/j.issn.1005-202X.2014.03.008]
[3]李 毅,李文荣,苏 进,等.基于CBCT非小细胞肺癌外放边界研究[J].中国医学物理学杂志,2014,31(04):5006.[doi:10.3969/j.issn.1005-202X.2014.04.008]
[4]刘建庭,王晋丽,郭瑞嵩,等.简化调强技术在脑转移瘤外照射中应用的剂量学研究[J].中国医学物理学杂志,2014,31(06):5244.[doi:10.3969/j.issn.1005-202X.2014.06.005]
[5]宁丽华,赵桂芝,张磊,等.全脑放疗伴随1~4 个脑转移瘤同期加量不同调强技术的剂量学研究[J].中国医学物理学杂志,2016,33(2):128.[doi:10.3969/j.issn.1005-202X.2016.02.005]
[6]陈旎,等.III期非小细胞肺癌三维适形与调强技术的剂量学比较[J].中国医学物理学杂志,2016,33(2):198.[doi:10.3969/j.issn.1005-202X.2016.02.019]
[7]段小娟,周一兵,钱金栋.脑转移瘤调强放疗最佳子野数目[J].中国医学物理学杂志,2016,33(7):668.[doi:10.3969/j.issn.1005-202X.2016.07.005]
　[J].Chinese Journal of Medical Physics,2016,33(2):668.[doi:10.3969/j.issn.1005-202X.2016.07.005]
[8]李毅,唐丰文,张晓智. 基于四维CT和锥形束CT确定非小细胞肺癌放疗靶区外放边界[J].中国医学物理学杂志,2016,33(9):892.[doi:10.3969/j.issn.1005-202X.2016.09.005]
　[J].Chinese Journal of Medical Physics,2016,33(2):892.[doi:10.3969/j.issn.1005-202X.2016.09.005]
[9]王锐濠,张书旭,谭剑明,等.最小机器跳数对非小细胞肺癌调强放疗计划设计的影响[J].中国医学物理学杂志,2016,33(11):1092.[doi:10.3969/j.issn.1005-202X.2016.11.003]
　[J].Chinese Journal of Medical Physics,2016,33(2):1092.[doi:10.3969/j.issn.1005-202X.2016.11.003]
[10]朱晟超,王远军.锥形束CT对非小细胞肺癌放疗摆位误差及放疗射线剂量的影响锥形束CT对非小细胞肺癌放疗摆位误差及放疗射线剂量的影响[J].中国医学物理学杂志,2017,34(2):109.[doi:10.3969/j.issn.1005-202X.2017.02.001]
　Effect of cone beam CT on setup error and radiation dose distribution in radiotherapy for nonsmall[J].Chinese Journal of Medical Physics,2017,34(2):109.[doi:10.3969/j.issn.1005-202X.2017.02.001]

备注/Memo

备注/Memo:
【收稿日期】2025-09-17 【基金项目】内蒙古自治区自然科学基金（2021MS08133）；北京医学奖励基金会肺癌医学青年专家委员会BEST基金（YXJL-BEST-B-01） 【作者简介】马晓云，主治医师，研究方向：肿瘤放疗及内科综合治疗，E-mail: M8880303Y@163.com 【通信作者】李全福，主任医师，硕士生导师，研究方向：肿瘤放疗及内科综合治疗，E-mail: 1729259137@qq.com
更新日期/Last Update: 2026-01-27